D
David E. Kandzari
Researcher at Duke University
Publications - 348
Citations - 19759
David E. Kandzari is an academic researcher from Duke University. The author has contributed to research in topics: Percutaneous coronary intervention & Conventional PCI. The author has an hindex of 55, co-authored 292 publications receiving 16299 citations. Previous affiliations of David E. Kandzari include Columbia University & University of Texas Southwestern Medical Center.
Papers
More filters
Journal ArticleDOI
A Controlled Trial of Renal Denervation for Resistant Hypertension
Deepak L. Bhatt,David E. Kandzari,John M. Flack,Barry T. Katzen,Martin B. Leon,Minglei Liu,Laura Mauri,Manuela Negoita,Sidney Cohen,Suzanne Oparil,Krishna J. Rocha-Singh,Raymond R. Townsend,George L. Bakris,Abstr Act +13 more
TL;DR: This blinded trial did not show a significant reduction of systolic blood pressure in patients with resistant hypertension 6 months after renal-artery denervation as compared with a sham control.
Journal ArticleDOI
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Laura Mauri,Dean J. Kereiakes,Robert W. Yeh,Priscilla Driscoll-Shempp,Donald E. Cutlip,P. Gabriel Steg,P. Gabriel Steg,Sharon-Lise T. Normand,Eugene Braunwald,Stephen D. Wiviott,David J. Cohen,David R. Holmes,Mitchell W. Krucoff,James B. Hermiller,Harold L. Dauerman,Daniel I. Simon,David E. Kandzari,Kirk N. Garratt,David P. Lee,Thomas K. Pow,Peter Ver Lee,Michael J. Rinaldi,Joseph M. Massaro,Joseph M. Massaro +23 more
TL;DR: Dual antiplatelet therapy beyond 1 year after placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events but was associated with an increased risk of bleeding.
Journal ArticleDOI
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Matthew J. Price,Peter B. Berger,Paul S. Teirstein,Jean-François Tanguay,Dominick J. Angiolillo,Douglas Spriggs,Sanjeev Puri,Mark Robbins,Kirk N. Garratt,Olivier F. Bertrand,Michael E. Stillabower,Joseph Aragon,David E. Kandzari,Curtiss T. Stinis,Michael S. Lee,Steven V. Manoukian,Christopher P. Cannon,Nicholas J. Schork,Eric J. Topol +18 more
TL;DR: In this paper, the authors evaluated the effect of high-dose compared with standard-dose clopidogrel in patients with high on-treatment platelet reactivity after percutaneous coronary intervention (PCI), but a treatment strategy for this issue was not well defined.
Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention
Matthew J. Price,Peter B. Berger,Paul S. Teirstein,Dominick J. Angiolillo,Douglas Spriggs,Sanjeev Puri,Mark Robbins,Kirk N. Garratt,Olivier F. Bertrand,Michael E. Stillablower,Joseph Aragon,David E. Kandzari,Curtiss T. Stinis,Michael S. Lee,Steven V. Manoukian,Christopher P. Cannon,Nicholas J. Schork,Eric J. Topol +17 more
TL;DR: Among patients with high on-treatment reactivity after PCI with drug-eluting stents, the use of high-dose clopidogrel compared with standard- dose clopIDogrel did not reduce the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or stent thrombosis.
Journal Article
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. Commentary
Eric L. Eisenstein,Kevin J. Anstrom,David F. Kong,Linda K. Shaw,Robert H. Tuttle,Daniel B. Mark,Judith M. Kramer,Robert A. Harrington,David B. Matchar,David E. Kandzari,Eric D. Peterson,Kevin A. Schulman,Robert M. Califf,Dean J. Kereiakes +13 more
TL;DR: The extended use of clopidogrel in patients with DES may be associated with a reduced risk for death and death or MI, and the appropriate duration for clopIDogrel administration can only be determined within the context of a large-scale randomized clinical trial.